Low-interest rates during the COVID-19 pandemic drove housing demand higher, incentivizing builders to start new projects. But now, higher rates are killing demand and construction is slowing down dramatically.
TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM
Concord Acquisition Corp III (the "Company") announced it had received a notification dated January 19, 2024 (the "Notice") from the New York Stock Exchange (the "NYSE") informing the Company that, because the number of